NAGE · XBRL financial data

Niagen Bioscience financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NAGE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	59,257	67,449	72,050	83,570	99,597	129,423
Cost of revenue	23,983	25,959	29,253	32,790	38,011	46,234
Gross profit	35,274	41,490	42,797	50,780	61,586	83,189
Research and development	3,732	3,832	4,826	4,958	6,016	6,330
General and administrative	30,448	36,379	28,286	24,983	18,375	27,057
Total operating expenses	55,128	68,563	61,425	56,379	53,860	66,910
Operating income (loss)	(19,854)	(27,073)	(18,628)	(5,599)	7,726	16,279
Interest income	—	—	—	—	1,129	2,127
Interest expense	71	55	—	—	—	—
Income tax expense (benefit)	—	—	—	0	305	810
Net income (loss)	(19,925)	(27,128)	(16,540)	(4,938)	8,550	17,382
Earnings per share, basic USD per share	(0.33)	(0.40)	(0.24)	(0.07)	0.11	0.22
Earnings per share, diluted USD per share	(0.33)	(0.40)	(0.24)	(0.07)	0.11	0.20
Weighted average shares, basic thousands of shares	61,067	67,185	69,729	74,985	75,929	79,178
Weighted average shares, diluted thousands of shares	61,067	67,185	69,729	74,985	78,125	85,436

Fiscal years (NAGE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	16,697	28,219	20,300	27,200	44,500	64,788
Accounts receivable	2,694	5,226	8,482	5,234	7,768	9,741
Inventory	11,683	13,601	14,677	14,525	9,192	20,424
Prepaid and other current assets	—	—	—	—	—	1,312
Total current assets	32,219	48,905	46,567	49,534	64,102	96,806
Property and equipment, net	3,206	—	—	—	—	—
Right-of-use asset	1,226	4,352	3,523	2,400	1,730	2,192
Total assets	38,358	57,840	54,057	54,964	68,278	106,406
Accounts payable	9,445	10,423	9,679	10,232	8,526	10,796
Accrued liabilities	6,133	6,481	7,337	9,493	7,817	7,722
Total current liabilities	16,476	17,613	17,869	20,622	17,948	19,919
Lease liability, non-current	997	4,154	3,539	2,563	1,657	1,815
Total liabilities	21,934	26,113	25,385	26,508	22,184	29,873
Accumulated deficit	(141,825)	(168,953)	(185,493)	(190,460)	(181,910)	(164,528)
Total stockholders' equity	16,424	31,727	28,672	28,456	46,094	76,533
Total liabilities and equity	38,358	57,840	54,057	54,964	68,278	106,406
Common shares outstanding (cover page) thousands of shares	66,739	68,309	74,838	75,309	77,750	80,080

Fiscal years (NAGE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(19,925)	(27,128)	(16,540)	(4,938)	8,550	17,382
Stock-based compensation	6,936	6,195	5,739	4,751	3,656	6,067
Net cash from operating activities	(10,600)	(24,163)	(15,098)	7,117	12,109	13,504
Net cash from investing activities	(165)	(409)	(334)	(143)	(143)	(292)
Proceeds from issuing common stock	4,856	26,740	7,747	0	—	—
Share repurchases	—	—	—	—	0	251
Net cash from financing activities	8,650	36,094	7,654	(90)	5,369	6,916
Net change in cash	(2,115)	11,522	(7,778)	6,884	17,335	20,128

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Niagen Bioscience	69,509	27,192	not reported	79.2M	—	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720,242	673,064	615,631*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Syndax Pharmaceuticals	135,941	83,298	(27,254)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Wave Life Sciences	197,315	13,158	(60,142)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
Cogent Biosciences	181,172	not reported	(77,271)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	62,643	57,480	(15,827)*	642.5M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
uniQure	98,442	5,196	(47,827)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	61,419	396,747*	24,094*	not reported	—	Q4 FY26 10-KJun 30, 2026
Intellia Therapeutics	106,128	7,659	(83,113)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.